Physician profile
Gregory Quin
NPI 1548260714
$3,778.77
in general payments reported to CMS, 2019-2025
21 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $398 · 2021: $1,147 · 2022: $716 · 2023: $558 · 2024: $158 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $991.14 | 2019-2025 | Farxiga, Airsupra |
| Allergan, INC. | $458.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.08 | 2019-2025 | Jardiance |
| Pfizer INC. | $134.81 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.10 | 2022-2023 | |
| Abbott Laboratories | $95.28 | 2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $83.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $79.91 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $79.25 | 2021 | |
| Astellas Pharma US INC | $75.12 | 2020-2025 | Veozah |
| Eisai INC. | $64.94 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.15 | 2021 | |
| Amneal Pharmaceuticals LLC | $40.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.88 | 2025 | Voquezna |
| Boston Scientific Corporation | $21.89 | 2025 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company LTD. | $18.90 | 2022 | |
| Biogen, INC. | $18.00 | 2021 | |
| Amgen INC. | $16.84 | 2022 | |
| Lilly USA, LLC | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Quin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.